- Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomideMei Yin C Polley
Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, Room A 808, Box 0372, San Francisco, California 94143 2167, USA
Neuro Oncol 12:274-82. 2010..Our analysis suggests that 6-month PFS may be an appropriate primary endpoint in the context of phase II upfront GBM trials in the TMZ era...
- Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiformeInas S Khayal
UCSF UCB Joint Graduate Group in Bioengineering, Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California 94158 2330, USA
Neuro Oncol 12:908-16. 2010..This is important because the mid-RT scan is currently not performed as part of the standard clinical care...
- Impact of bevacizumab chemotherapy on craniotomy wound healingAaron J Clark
Department of Neurological Surgery, University of California, San Francisco, California 94143 0112, USA
J Neurosurg 114:1609-16. 2011..Phase II trials reported 4%-6% impaired wound healing for bevacizumab initiated postoperatively. The effect of preoperative bevacizumab on subsequent craniotomy healing has not been addressed...
- Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBMRadhika Srinivasan
Department of Radiology and Biomedical Imaging, 1700 4th Street, Byers Hall, Suite 301, San Francisco, CA 94143 2532, USA
Neuro Oncol 12:1152-61. 2010..Low levels of MCI for tumor were associated with a reduced apparent diffusion coefficient and elevated choline-N-acetyl-aspartate index derived from in vivo MR images...